Investigating a new pathway that helps triple-negative breast cancer grow and spread
A novel cellular identity regulatory pathway that drives anokis resistance-mediated TNBC growth and metastasis
This study is looking at how triple-negative breast cancer cells manage to survive when they should die after breaking away from their surroundings, and by finding certain proteins that help them do this, the researchers hope to discover new ways to treat this tough type of breast cancer.
Quick facts
| Grant type | R03 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Alabama at Birmingham NIH-funded |
| Lab location | 1 site (Birmingham, United States) |
| Project ID | NIH-10947156 on NIH RePORTER |
What this research studies
This research focuses on understanding how triple-negative breast cancer (TNBC) cells resist a process called anoikis, which normally causes cells to die when they detach from their surroundings. By identifying specific protein kinases that contribute to this resistance, the study aims to uncover new therapeutic targets for TNBC treatment. The researchers will use advanced screening techniques to pinpoint these kinases and evaluate their role in TNBC growth and metastasis. This could lead to the development of more effective treatments for patients suffering from this aggressive form of breast cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are women diagnosed with triple-negative breast cancer, particularly those with advanced or metastatic disease.
Not a fit: Patients with non-triple-negative breast cancer subtypes may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of new therapies that significantly improve outcomes for patients with triple-negative breast cancer.
How similar studies have performed: Previous research has successfully identified therapeutic targets in other cancer types using similar approaches, suggesting potential for success in this area as well.
Where this research is happening
Birmingham, United States
- University of Alabama at Birmingham — Birmingham, United States (Active)
Researchers
- Principal investigator: Gupta, Romi — University of Alabama at Birmingham
- Study coordinator: Gupta, Romi
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.